Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented disease progression during imatinib and sunitinib therapy OR intolerance to imatinib and/or sunitinib~* At least one measurable site of disease on CT/MRI scan~* PS≤2~* Normal organ, electrolyte, and bone marrow function~Exclusion Criteria:~* Previous treatment with nilotinib or any other drug in this class or other targeted therapy~* Treatment with any cytotoxic and/or investigational drug ≤ 4 weeks prior to study entry~* Impaired cardiac function~* Use of coumarin derivatives (i.e. warfarin)~* Women who are pregnant or lactating~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nilotinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).